イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - cabergoline - oral tablet - 1mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - cabergoline - oral tablet - 1mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - cabergoline - oral tablet - 1mg

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals

カナダ - 英語 - Health Canada

pfizer canada ulc - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose; leucine - for the management of the signs and symptoms of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy( see contraindications, precautions and adverse effects)

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline, quantity: 1 mg - tablet, uncoated - excipient ingredients: leucine; lactose - for the management of the signs and symptoms of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy( see contraindications, precautions and adverse effects)

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

avera mckennan hospital - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including  echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sola pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see  warnings ).